Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model

Enterococcus faecium strains are commonly resistant to vancomycin and β-lactams. In addition, E. faecium often causes biofilm-associated infections and these infections are difficult to treat. In this context, we investigated the activity of dosing regimens using daptomycin (DAP) (8, 10, 12, and 14...

Full description

Autores:
Jahanbakhsh, Seyedehameneh
Singh, Nivedita B.
Yim, Juwon
Kebriaei, Razieh
Smith, Jordan R.
Lev, Katherine L.
Tran, Truc T.
Rose, Warren
Arias, Cesar A
Rybak, Michael Joseph
Tipo de recurso:
Article of journal
Fecha de publicación:
2020
Institución:
Universidad El Bosque
Repositorio:
Repositorio U. El Bosque
Idioma:
eng
OAI Identifier:
oai:repositorio.unbosque.edu.co:20.500.12495/3459
Acceso en línea:
http://hdl.handle.net/20.500.12495/3459
https://doi.org/10.1128/aac.02074-19
https://repositorio.unbosque.edu.co
Palabra clave:
Enterococcus faecium
Cefalosporinas
Resistencia betalactámica
Biofilms
Combination therapy
Daptomycin
Rights
openAccess
License
Acceso abierto
id UNBOSQUE2_7885c777db2891403ddffc6f3d6ac4bb
oai_identifier_str oai:repositorio.unbosque.edu.co:20.500.12495/3459
network_acronym_str UNBOSQUE2
network_name_str Repositorio U. El Bosque
repository_id_str
dc.title.spa.fl_str_mv Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model
dc.title.translated.spa.fl_str_mv Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model
title Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model
spellingShingle Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model
Enterococcus faecium
Cefalosporinas
Resistencia betalactámica
Biofilms
Combination therapy
Daptomycin
title_short Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model
title_full Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model
title_fullStr Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model
title_full_unstemmed Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model
title_sort Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm model
dc.creator.fl_str_mv Jahanbakhsh, Seyedehameneh
Singh, Nivedita B.
Yim, Juwon
Kebriaei, Razieh
Smith, Jordan R.
Lev, Katherine L.
Tran, Truc T.
Rose, Warren
Arias, Cesar A
Rybak, Michael Joseph
dc.contributor.author.none.fl_str_mv Jahanbakhsh, Seyedehameneh
Singh, Nivedita B.
Yim, Juwon
Kebriaei, Razieh
Smith, Jordan R.
Lev, Katherine L.
Tran, Truc T.
Rose, Warren
Arias, Cesar A
Rybak, Michael Joseph
dc.subject.decs.spa.fl_str_mv Enterococcus faecium
Cefalosporinas
Resistencia betalactámica
topic Enterococcus faecium
Cefalosporinas
Resistencia betalactámica
Biofilms
Combination therapy
Daptomycin
dc.subject.keywords.spa.fl_str_mv Biofilms
Combination therapy
Daptomycin
description Enterococcus faecium strains are commonly resistant to vancomycin and β-lactams. In addition, E. faecium often causes biofilm-associated infections and these infections are difficult to treat. In this context, we investigated the activity of dosing regimens using daptomycin (DAP) (8, 10, 12, and 14 mg/kg of body weight/ day) alone and in combination with ceftaroline (CPT), ampicillin (AMP), ertapenem (ERT), and rifampin (RIF) against 2 clinical strains of biofilm-producing vancomycinresistant Enterococcus faecium (VREfm), namely, strains S447 and HOU503, in an in vitro biofilm model. HOU503 harbors common LiaS and LiaR substitutions, whereas S447 lacks mutations associated with the LiaFSR pathway. MIC results demonstrated that both strains were susceptible to DAP and resistant to CPT, AMP, ERT, and RIF. The 168-h pharmacokinetic/pharmacodynamic (PK/PD) CDC biofilm reactor models (simulating human antibiotic exposures) were used with titanium and polyurethane coupons to evaluate the efficacy of antibiotic combinations. DAP 12 and 14 achieved bactericidal activity against S447 but lacked such effect against HOU503. Addition of ERT and RIF enhanced DAP activity, allowing DAP 8 and 10 plus ERT or RIF to produce bactericidal activity against both strains at 168 h. While DAP 8 and 10 plus CPT improved killing, they did not reach bactericidal reduction against S447. Combination of AMP, CPT, ERT, or RIF resulted in enhanced and bactericidal activity for DAP against HOU503 at 168 h. Our data provide further support for the use of combinations of DAP with AMP, ERT, CPT, and RIF in infections caused by biofilm producing VREfm. Further research involving DAP combinations against biofilm-producing enterococci is warranted.
publishDate 2020
dc.date.accessioned.none.fl_str_mv 2020-07-10T20:43:26Z
dc.date.available.none.fl_str_mv 2020-07-10T20:43:26Z
dc.date.issued.none.fl_str_mv 2020
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.local.none.fl_str_mv Artículo de revista
dc.type.coar.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
format http://purl.org/coar/resource_type/c_6501
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12495/3459
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1128/aac.02074-19
dc.identifier.instname.spa.fl_str_mv instname:Universidad El Bosque
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourl.none.fl_str_mv https://repositorio.unbosque.edu.co
url http://hdl.handle.net/20.500.12495/3459
https://doi.org/10.1128/aac.02074-19
https://repositorio.unbosque.edu.co
identifier_str_mv instname:Universidad El Bosque
reponame:Repositorio Institucional Universidad El Bosque
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartofseries.spa.fl_str_mv Antimicrobial agents and chemotherapy, 1098-6596, Vol. 64, Nro. 5, 2020
dc.relation.uri.none.fl_str_mv https://aac.asm.org/content/64/5/e02074-19.abstract
dc.rights.local.spa.fl_str_mv Acceso abierto
dc.rights.accessrights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
Acceso abierto
dc.rights.creativecommons.none.fl_str_mv 2020-05-01
rights_invalid_str_mv Acceso abierto
http://purl.org/coar/access_right/c_abf2
2020-05-01
eu_rights_str_mv openAccess
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv American Society for Microbiology
institution Universidad El Bosque
bitstream.url.fl_str_mv http://18.204.144.38/bitstreams/129c45a8-976b-44ae-afe3-ea86e6131681/download
http://18.204.144.38/bitstreams/49520e42-6ca6-4ee8-8d2b-8c5c5fd885d1/download
bitstream.checksum.fl_str_mv 8a4605be74aa9ea9d79846c1fba20a33
7210a811635d1799e7c05fee5d259be7
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv DSpace Pre-instalado Biteca S.A.S
repository.mail.fl_str_mv bibliotecas@biteca.com
_version_ 1814100674766438400
spelling Jahanbakhsh, SeyedehamenehSingh, Nivedita B.Yim, JuwonKebriaei, RaziehSmith, Jordan R.Lev, Katherine L.Tran, Truc T.Rose, WarrenArias, Cesar ARybak, Michael Joseph2020-07-10T20:43:26Z2020-07-10T20:43:26Z2020http://hdl.handle.net/20.500.12495/3459https://doi.org/10.1128/aac.02074-19instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquehttps://repositorio.unbosque.edu.coapplication/pdfengAmerican Society for MicrobiologyAntimicrobial agents and chemotherapy, 1098-6596, Vol. 64, Nro. 5, 2020https://aac.asm.org/content/64/5/e02074-19.abstractImpact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm modelImpact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in Vitro biofilm modelArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttp://purl.org/coar/version/c_970fb48d4fbd8a85Enterococcus faeciumCefalosporinasResistencia betalactámicaBiofilmsCombination therapyDaptomycinEnterococcus faecium strains are commonly resistant to vancomycin and β-lactams. In addition, E. faecium often causes biofilm-associated infections and these infections are difficult to treat. In this context, we investigated the activity of dosing regimens using daptomycin (DAP) (8, 10, 12, and 14 mg/kg of body weight/ day) alone and in combination with ceftaroline (CPT), ampicillin (AMP), ertapenem (ERT), and rifampin (RIF) against 2 clinical strains of biofilm-producing vancomycinresistant Enterococcus faecium (VREfm), namely, strains S447 and HOU503, in an in vitro biofilm model. HOU503 harbors common LiaS and LiaR substitutions, whereas S447 lacks mutations associated with the LiaFSR pathway. MIC results demonstrated that both strains were susceptible to DAP and resistant to CPT, AMP, ERT, and RIF. The 168-h pharmacokinetic/pharmacodynamic (PK/PD) CDC biofilm reactor models (simulating human antibiotic exposures) were used with titanium and polyurethane coupons to evaluate the efficacy of antibiotic combinations. DAP 12 and 14 achieved bactericidal activity against S447 but lacked such effect against HOU503. Addition of ERT and RIF enhanced DAP activity, allowing DAP 8 and 10 plus ERT or RIF to produce bactericidal activity against both strains at 168 h. While DAP 8 and 10 plus CPT improved killing, they did not reach bactericidal reduction against S447. Combination of AMP, CPT, ERT, or RIF resulted in enhanced and bactericidal activity for DAP against HOU503 at 168 h. Our data provide further support for the use of combinations of DAP with AMP, ERT, CPT, and RIF in infections caused by biofilm producing VREfm. Further research involving DAP combinations against biofilm-producing enterococci is warranted.Acceso abiertohttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessAcceso abierto2020-05-01LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://18.204.144.38/bitstreams/129c45a8-976b-44ae-afe3-ea86e6131681/download8a4605be74aa9ea9d79846c1fba20a33MD52THUMBNAILVillamil-Gómez W.E., Rodríguez-Morales A.J., Uribe-García A.M._2016.jpgVillamil-Gómez W.E., Rodríguez-Morales A.J., Uribe-García A.M._2016.jpgimage/jpeg5775http://18.204.144.38/bitstreams/49520e42-6ca6-4ee8-8d2b-8c5c5fd885d1/download7210a811635d1799e7c05fee5d259be7MD5320.500.12495/3459oai:18.204.144.38:20.500.12495/34592022-05-05 17:37:48.575metadata.onlyhttp://18.204.144.38DSpace Pre-instalado Biteca S.A.Sbibliotecas@biteca.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